Can pyroptosis be a new target in rheumatoid arthritis treatment?

Dengqiang Wu1, Yujie Li2, Ranxing Xu1

  • 1Department of Clinical Laboratory, Ningbo No.6 Hospital, Ningbo, China.

PubMed

Insights

Rheumatoid arthritis (RA) involves chronic inflammation and joint destruction. This review explores pyroptosis, a cell death process, as a potential new target for RA treatment and drug development.

Area of Science:

  • Immunology
  • Cell Biology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and destruction.
  • Current treatments like NSAIDs, glucocorticoids, and DMARDs manage symptoms but don't offer a complete cure.
  • Understanding RA's underlying mechanisms is crucial for developing radical treatments.

Purpose of the Study:

  • To review the discovery and mechanisms of pyroptosis.
  • To outline current therapeutic strategies for RA.
  • To investigate the role of pyroptosis in RA pathogenesis and its potential as a therapeutic target.

Main Methods:

  • Literature review of pyroptosis.
  • Analysis of RA pathogenesis.
  • Exploration of pyroptosis-targeting strategies for RA.

Main Results:

  • Pyroptosis is a pro-inflammatory programmed cell death (PCD) characterized by cell membrane rupture and release of inflammatory factors.
  • Evidence suggests pyroptosis plays a role in RA development and progression.
  • Targeting pyroptosis may offer new avenues for RA treatment.

Conclusions:

  • Pyroptosis is implicated in the inflammatory mechanisms of rheumatoid arthritis.
  • Targeting pyroptosis presents a promising strategy for novel RA therapies.
  • Further research into pyroptosis could lead to the development of new drugs for RA treatment.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
198
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218